Clinical Trial Detail

NCT ID NCT02513472
Title Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eisai Inc.
Indications

triple-receptor negative breast cancer

Therapies

Eribulin + Pembrolizumab

Age Groups: adult

No variant requirements are available.